CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 872 enrolled
Drug / intervention
Vitamin C +1 moredrug
Likely dose
Vitamin C 50 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03680274
NCT03680274Phase 3Completed
CompareCT.gov

Lessening Organ Dysfunction With VITamin C (LOVIT)

Université de Sherbrooke·interventional·Posted Sep 21, 2018·Updated Apr 4, 2022

In Brief

A Phase 3 clinical trial evaluating Vitamin C and Control for Sepsis and 5 related conditions. Completed, enrolled 872 participants across 1 site.

Detailed Summary

LOVIT is a multicentre concealed-allocation parallel-group blinded randomized controlled trial to ascertain the effect of high-dose intravenous vitamin C compared to placebo on mortality or persistent organ dysfunction at 28 days in septic intensive care unit patients. Patients with COVID-19 are considered eligible for this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis, Vitamin C, Intensive Care Unit, COVID-19, Pandemic, Coronavirus
CountriesCanada
CollaboratorsLotte & John Hecht Memorial Foundation

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedSep 21, 2018
Enrollment StartNov 8, 2018
Primary CompletionAug 15, 2021
Study CompletionJan 24, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.8 years ago

Interventions

Vitamin Cdrug

Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).

Controlother

Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.